Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. AIM ImmunoTech's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-3.02 Mil. AIM ImmunoTech's Revenue for the
three
months ended in Mar. 2026 was $0.02 Mil. Therefore, AIM ImmunoTech's pretax margin for the quarter that ended in Mar. 2026 was -13,740.91%.
The historical rank and industry rank for AIM ImmunoTech's Pretax Margin % or its related term are showing as below:
AIM'
s Pretax Margin % Range Over the Past 10 Years
Min: -15861.36 Med: -9511.3 Max: -1889.93
Current: -14123.4
AIM's Pretax Margin % is ranked worse than 94.18% of 945
companies
in the Biotechnology industry
Industry Median: -90.63
vs AIM: -14123.40
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
AIM ImmunoTech Pretax Margin % Related Terms
AIM ImmunoTech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM vs BGMS, FBLG, CLGN: Pretax Margin % Comparison
For the Biotechnology subindustry, AIM ImmunoTech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AIM) has a Pretax Margin % of -13,740.91% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on AIM ImmunoTech and its competitors. According to the industry distribution chart, AIM ImmunoTech ranks #890 out of 945 companies in the Biotechnology industry, placing it in the top 94.2%.
Is AIM ImmunoTech's Pretax Margin % too high?
AIM ImmunoTech's current Pretax Margin % is -13,740.91%. Based on the distribution chart, AIM ImmunoTech ranks #890 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Pretax Margin % compare to BGMS and FBLG?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #890 out of 945 companies for Pretax Margin %. This places AIM ImmunoTech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Pretax Margin % is -13,740.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current Pretax Margin % is -13,740.91%. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Pretax Margin % is -13,740.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
Pretax Margin %: -13,740.91%
GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for AIM
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
